CK Life Sciences Int'l., (Holdings) Inc. provided an update on the ongoing Phase III clinical study of seviprotimut-L, an investigational melanoma vaccine candidate of Polynoma LLC ("Polynoma"), the company's wholly-owned U.S. immuno-oncology focused biopharmaceutical subsidiary. The Company announced that Polynoma will be presenting final analysis of clinical data from Part B1 of MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), a Phase III clinical study of seviprotimut-L, at the American Society of Clinical Oncology (ASCO)'s ASCO20 Virtual Scientific Program, to be held online from 29 to 31 May 2020. MAVIS is a multicenter, double-blind, placebo-controlled adaptive Phase III trial to assess the safety and efficacy of seviprotimut-L, with primary endpoints of recurrence-free survival (RFS) and overall survival (OS) in patients with American Joint Committee on Cancer (AJCC) Stage IIB/C, IIIA, IIIB/C melanoma at high risk of recurrence after definitive surgical resection, and is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. Polynoma considers that the final analysis of Part B1 of MAVIS reinforces the findings from the interim analysis last year, suggesting improved outcomes with seviprotimut-L in Stage IIB/IIC melanoma patients, particularly in those aged under 60 and those with disease with ulceration. Polynoma believes that seviprotimut-L will be an important new option for the adjuvant treatment of patients with localised melanoma and that these data show promise for seviprotimut-L as a vaccine-based treatment of melanoma. Polynoma will be advancing seviprotimut-L into the definitive part of the MAVIS study.